PawOrigins Begins a New Chapter With Veterinarian-Formulated Pet Longevity Products and Rescue Support
Building on its reputation for science-backed solutions that address anxiety in dogs, the company is now broadening its focus to long-term vitality and holistic care. With a fulfillment operation in New Castle, Delaware, and a growing online presence, the brand aims to redefine what pet wellness means in the modern e-commerce landscape.
Dr. Kathryn Dench: PawOrigins Chief Scientific Advisor
Supporting Anxious Dogs Nationwide
Anxiety is one of the leading challenges facing dogs today, especially those in shelters or transitioning to new homes. PawOrigins' flagship product, Happy-Furever™, developed by Cambridge-educated veterinarian Dr. Kathryn Dench (Chief Scientific Advisor), offers a natural approach to prescription medications in calming stressed dogs.
'We're empowering pets and the people who love them with solutions that focus on emotional balance and long-term vitality,' says Dr. Dench. 'Having my own 3 rescue dogs, I know how difficult it is, and I wasn't content with putting them on a lifetime of prescription medications.'
Earlier this year, PawOrigins extended its mission by donating over $11,000 worth of calming products to rescue shelters nationwide. This initiative was created to support staff and volunteers working with some of the most anxious and vulnerable dogs and has already helped many rescues adjust more easily to foster homes and adoption.
'Our intention was really to see how we can help rescues with anxiety, we know this to be a huge problem from speaking with our customer base,' says CEO Mike Eli.
A New Chapter In Natural Pet Care And Longevity
Moreover, as part of its evolving mission, PawOrigins continues to innovate with veterinarian-formulated products designed to support dogs through every stage of life. The brand brings together trusted ingredients, veterinary expertise, and U.S.-based manufacturing to make holistic care more accessible and affordable for pet parents with anxious or sensitive dogs.
'This is just the beginning of an exciting new chapter for us ,' says CEO Mike Eli. 'We're focused on developing natural longevity solutions, working closely with veterinarians and expert formulators to help dogs not only live longer but enjoy healthier, happier years with their families.'
With more pet parents seeking natural, holistic alternatives to support their dogs' long-term health, PawOrigins is working hard to design solutions that go beyond symptom relief, supporting immune health, mobility, and cognitive vitality.
To explore PawOrigins' full range of products, visit https://paworigins.com.
PawOrigins Logo
About PawOrigins
PawOrigins® is a mission-driven pet wellness company incorporated in Sheridan, Wyoming, with operations based in New Castle, Delaware. Founded to support dogs' long-term vitality and emotional balance, PawOrigins® creates science-backed, natural pet care solutions for pet parents and rescue organizations alike. With a commitment to helping dogs at every chapter of life, the brand advocates for better health, stronger bonds, and compassionate transitions from shelters into loving homes.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
33 minutes ago
- Associated Press
American Kidney Fund Activates Disaster Relief Program to Provide Aid to Dialysis and Post-Transplant Patients Impacted by Flooding in Texas Hill Country
ROCKVILLE, Md., July 08, 2025 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) has activated its Disaster Relief Program to assist dialysis and post-transplant patients living in areas that have been impacted by the devastating floods in central Texas. AKF's Disaster Relief Program is the nation's only rapid-response system that provides emergency financial aid to dialysis and recent transplant patients. The catastrophic flooding struck on Friday on the Guadalupe River near Kerrville killing more than 100 people and causing extensive damage. Evacuation is particularly challenging for people who need to receive dialysis treatments three times per week. 'We are heartbroken to hear about the loss of life and devastation in Texas,' said LaVarne A. Burton, AKF President and CEO. 'In this time of great need, people living with kidney failure are particularly vulnerable, as they rely on dialysis treatments and specific medications and foods to maintain their health. AKF is ready to provide critical assistance to Texas patients who have been impacted by this disaster.' Emergency grants of $250 are available for dialysis and post-transplant patients living in the following counties in Texas: Kerr, Travis, Burnet, Kendall, Williamson and Tom Green. Disaster relief grants help patients with low incomes replace lost medications and kidney-friendly foods (which may be spoiled due to power outages), pay for temporary housing and transportation to treatment, and replace clothing and personal essentials lost due to the natural disaster or the need to evacuate with little to no notice. To donate in support of AKF's disaster relief efforts for the Texas floods, visit AKF's website. AKF covers the administrative costs of this program so that 100% of donations may go directly to patients in need. People with kidney failure are more susceptible to difficulties during a natural disaster, as interruptions to dialysis treatments can put them at risk for being hospitalized. AKF has developed a resource page for patients impacted by the floods, which can be accessed here. AKF has been providing emergency disaster financial assistance to kidney patients throughout all the major disasters that have struck the United States and its territories for the past three decades. Last year, AKF distributed more than 1,600 disaster relief grants totaling nearly $420,000 to people affected by hurricanes and severe storms. Dialysis and recent kidney transplant patients who need emergency financial aid should contact a social worker at their dialysis or transplant clinic for information on applying for aid or apply directly at About the American Kidney Fund The American Kidney Fund (AKF) fights kidney disease on all fronts as the nonprofit with the greatest direct impact on people with kidney disease. AKF works on behalf of the 1 in 7 American adults living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through post-transplant living. AKF fights for kidney health for all through programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy. AKF is one of the nation's top-rated nonprofits, investing 96 cents of every donated dollar in programs, and it has received 24 consecutive 4-star ratings from Charity Navigator as well as the Platinum Seal of Transparency from Candid, formerly known as GuideStar. For more information, please visit or connect with AKF on Facebook, Bluesky, X, Instagram and LinkedIn. Nancy Gregory American Kidney Fund (240) 292-7077 [email protected]
Yahoo
an hour ago
- Yahoo
Market to Surpass $120 Billion by 2034 - Increased Strategic Merger and Initiatives to Meet Rising Demand
The anti-obesity drugs market, valued at USD 3.20 billion in 2024, is propelled by rising obesity prevalence worldwide, aiming for USD 120.32 billion by 2034 at 43.72% CAGR. Key drivers include FDA-approved drugs like Liraglutide, strategic mergers, regulatory support, and rising awareness. Top players include Novo Nordisk and Eli Lilly. Anti-Obesity Drugs Market Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The "Anti-Obesity Drugs Market Report and Forecast 2025-2034" report has been added to anti-obesity drugs market was valued at USD 3.20 Billion in 2024, driven by rising prevalence of obesity across the 8 major markets. The market is expected to grow at a CAGR of 43.72% during the forecast period of 2025-2034, with the values likely to reach USD 120.32 Billion by 2034. Anti-Obesity Drugs Market OverviewAnti-obesity drugs target different aspects of weight management such as appetite suppression, fat absorption, and metabolic enhancement. There are several anti-obesity drugs approved by the United States Food and Drug Administration (FDA) for long-term use, including Bupropion-naltrexone (Contrave), Liraglutide (Saxenda), Orlistat (Xenical, Alli), Phentermine-topiramate (Qsymia), and Semaglutide (Wegovy), among others. Some weight loss medications like semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound) can help in reducing body weight by 20%.The anti-obesity drugs market growth is driven by the rising prevalence of obesity worldwide, increasing awareness about the health risks associated with obesity, and growing partnerships in obesity-related research. Furthermore, the surge in drug approvals by health regulatory agencies and innovation in drug development are some of the factors that are expected to positively influence the market Drugs Market Growth Drivers Rising Prevalence of Obesity to Foster the Market Landscape SignificantlyThe market is driven by rising prevalence of obesity which makes an individual prone to various health complications such as diabetes, cardiovascular diseases, and certain cancers. According to the World Health Organization (WHO), in 2022, around 2.5 billion adults (18 years or older) were overweight, out of which around 890 million adults were living with obesity. This equates to about 43% of the adults being overweight which shows an increase from the 1990, when 25% of adults aged 18 years and above were overweight. In addition, as per the latest World Obesity Atlas 2023, it is expected that the number of individuals falling in the overweight and obesity category will reach 4 billion by 2035. This indicates that every 1 in 5 women and 1 in 7 men, will be living with obesity by Strategic Merger and Initiatives to Meet Rising Anti-Obesity Drugs Market DemandOne of the significant market trends is the rise in strategic merger and acquisition initiatives taken by the key market players to expand production capacities and support the development of novel drug pipelines. Recently, in January 2024, Roche completed the acquisition of Carmot Therapeutics Inc. dedicated in developing the therapeutics for the people living with metabolic diseases including obesity and diabetes. Further, rising investments aimed at introducing safer and more efficient anti-obesity drugs in the market are also anticipated to accelerate market growth. In January 2024, Adipo Therapeutics closed a USD 1.9 million seed financing gap to advance the treatment of Type 2 diabetes and obesity. Market Segmentation Based on Product Type is Anticipated to Witness Substantial GrowthBy drugs, the market is segmented into Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine, and Tirzepatide. Each anti-obesity drug works on distinct mechanisms and shows different effects on weight management. Among the different anti-obesity drugs, the two anti-obesity drugs that have been approved for long-term usage are sibutramine and orlistat. However, they can even cause minor side-effects such as flatulence and Drugs Market Analysis by RegionBased on region, United States is the market is witnessing significant growth which can attributed to an advanced healthcare system offering access to various anti-obesity drugs to the huge patient population. With 78% of adults in the United States estimated to be overweight or obese by 2030, the rising prevalence of obesity in the region is poised to propel the market growth in the coming years. In addition, the increased funding, and investments to support the development of novel weight loss drugs is expected to augment the anti-obesity drugs market also holds a high market value, owing to the presence of leading market players in the region. Moreover, the dominance of the regional market is a result of the rising adoption of obesity treatment solutions and growing investments in obesity research and drug development. India is projected to witness substantial growth. It can be accredited to changing lifestyle of the people that can result in Drugs Market TrendsIncreased Focus on Combination TherapiesThere is a growing interest in combination therapies that target multiple pathways to induce weight loss. Such combinations can offer better efficacy as compared to conventional Patient AwarenessThere is an increased awareness and acceptance of obesity as a chronic disease requiring medical intervention, rather than just lifestyle changes. This shift is contributing to the rising anti-obesity drugs market SupportRegulatory agencies are providing transparent guidelines and support for the development and approval of anti-obesity drugs. This includes fast-track designations and approvals for drugs that exhibit significant benefits in clinical Use of GLP-1 Receptor AgonistsGlucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for diabetes treatment, are increasingly preferred for obesity management due to their ability to induce weight loss. Key Attributes: Report Attribute Details No. of Pages 400 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $3.2 Billion Forecasted Market Value (USD) by 2034 $120.32 Billion Compound Annual Growth Rate 43.7% Regions Covered Global Supplier Landscape GlaxoSmithKline PLC Pfizer Inc. Novo Nordisk A/S Rhythm Pharmaceuticals KVK Tech Inc. Currax Pharmaceuticals LLC CHEPLAPHARM Arzneimittel GmbH Vivus LLC Gelesis Holding Inc. Boehringer Ingelheim International GmbH Eli Lilly and Company Anti-Obesity Drugs Market SegmentationBreakup by Drug Type Semaglutide Phentermine/Topiramate Naltrexone/Bupropion Liraglutide Gelesis 100 Orlistat Phentermine Methamphetamine Tirzepatide Others Breakup by Drug Class Amphetamine GLP-1 Receptor Agonist Lipase Inhibitor Others Breakup by Mechanism of Action Centrally Acting Drugs Peripherally Acting Drugs Breakup by Prescription Type Prescription Drugs Over The Counter Drugs Breakup by Distribution Channel Hospital Pharmacies Drug Store & Retail Pharmacies Online Pharmacies Breakup by Region United States EU-4 and the United Kingdom Germany France Italy Spain United Kingdom Japan India For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Anti-Obesity Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Dr. Anosh Ahmed Expands Global Healthcare Leadership Through New Community Health Initiative
Chicago-based physician announces expansion of charitable programs focused on healthcare access and community wellnessImage of Dr. Anosh Ahmed CHICAGO, July 08, 2025 (GLOBE NEWSWIRE) -- Dr. Anosh Ahmed, a physician, entrepreneur, and global healthcare leader, has announced a new initiative to broaden access to healthcare resources in underserved communities across the United States and internationally. Known for his commitment to ethical leadership and community support, Dr. Ahmed's latest efforts are aimed at improving patient-centered care and strengthening healthcare infrastructure through charitable outreach and strategic partnerships. Building on years of leadership in medical services and logistics, Dr. Ahmed's new initiative will support projects that enhance wellness access, increase community outreach, and promote ethical standards in healthcare delivery. 'Our mission is to support communities that are too often overlooked,' says Dr. Ahmed. 'We're focusing on transparency, sustainability, and care models that empower both providers and patients.' Supporting Underserved Communities Through his foundation and nonprofit partnerships, Dr. Ahmed has provided support to a wide range of health-focused programs, from mobile clinics and outreach education to capacity-building efforts in rural areas. The new initiative will continue this work by offering grants, technical support, and health education campaigns in areas with limited resources. Highlights of the initiative include: Expansion of mobile and community-based care programs Support for local healthcare training and infrastructure Collaborations with charitable organizations and clinics Resource delivery and funding for basic medical supplies Dr. Ahmed emphasizes that transparency, compassion, and cultural sensitivity are the foundation of every program. 'Good healthcare means meeting people where they are and listening to what they need,' he adds. About Dr. Anosh Ahmed Dr. Anosh Ahmed is a Chicago-based physician, entrepreneur, and philanthropist with a mission to promote ethical and accessible healthcare worldwide. He has led numerous charitable and healthcare delivery initiatives in the U.S. and abroad, earning recognition for his leadership in community-based outreach and sustainable medical programs. Media Contact:Sandra Gomezlegal@ (346) 678-7004https:// A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
